The study used data from national health registries to link groups to seasonal vaccinations at an individual level and identified 54,559 pregnant women and 491,403 individuals <65 years with chronic conditions (≥2 hospital contacts for selected chronic conditions).
Ms Cecilie Seeger-Skaaning (Statens Serum Institut, Denmark) presented the results [1]. A total of 26.0% and 17.0% of pregnant women received influenza and COVID-19 vaccines, respectively. Among individuals <65 years with chronic conditions, 31.3% and 21.0% received influenza and COVID-19 vaccines, while vaccination uptake was almost 80% for both vaccines in individuals aged ≥65 years. Among pregnant women, vaccine uptake increased with age, showing a 4- to 5-fold increase in the odds of vaccination for the 35- to 45-year-old age group compared to the 18- to 24-year-old age group. Similarly, the odds of vaccination uptake increased with age in individuals <65 years with chronic conditions, with adjusted odds ratios (ORs) of 6.38 (95% CI 6.20-6.55) for influenza and 9.14 (95% CI 8.81–9.48) for COVID-19 vaccination when comparing the 60–64 with the 18-29 years age group. Another determinant of lower uptake in both populations was having a country of origin outside of Denmark.
“Vaccination uptake in pregnant women and individuals <65 years with chronic conditions is much lower than in adults aged 65 and older”, said Ms Seeger-Skaaning. “We see that influenza vaccine uptake is consistently higher than COVID-19 vaccine uptake among all age groups, and that age and country of origin are determinants for vaccination.” However, Ms Seeger-Skaaning added that a pilot program using tailored invitations showed increased vaccination regardless of age or country of origin, a strategy which could be used in the future to increase uptake.
- Moustsen-Helms IR, et al. Determinants of influenza and COVID-19 vaccine uptake among pregnant women and high-risk individuals. 6th ESCMID Vaccines, 10–13 September 2025, Lisbon, Portugal.
Copyright ©2025 Medicom Publishing Group
Posted on
Table of Contents: ESCMID Vaccines 2025
Featured articles
Real-world data confirm PCV20 effectiveness against pneumococcal disease in adults aged ≥65 years
Emerging and Future Vaccines
Where do we stand with vaccination for haemolytic streptococci?
The future looks promising for tuberculosis vaccination
Where do alternative vaccine administration routes fit in the clinical landscape?
Malaria immunisation beyond subunit vaccines: Current progress
SARI Definitions and Vaccine Effectiveness
Case definition discrepancies influence VE outcomes
Pneumococcal Vaccination
A quarter of US children have incomplete pneumococcal vaccination by age 2
V116 shows promise for adults at risk of pneumococcal disease
Real-world data confirm PCV20 effectiveness against pneumococcal disease in adults aged ≥65 years
The V116 pneumococcal vaccine is a new option in children at risk for pneumococcal disease
Influenza and COVID-19 Vaccination
Omicron XBB.1.5 vaccination provides effective, but rapidly waning protection in immunocompromised individuals
Intranasal COVID-19 vaccine shows promising results in preclinical mouse models
Influenza vaccine in children shows moderate, broad protection during the 2024-2025 season
Lower age is linked to reduced uptake of influenza and COVID-19 vaccination
RSV vaccination and Immunisation
Combination respiratory vaccines show promise but face key challenges
Adjuvanted RSVPreF3 demonstrates high real-world effectiveness in the USA
RSV immunisation: Maternal versus direct infant immunisation
European pregnant women show openness to maternal RSV vaccination
Infants immunised with nirsevimab have a lower risk of respiratory-related recurrent hospitalisation
Adjuvanted RSVPreF3 can be co-administered with a COVID-19 mRNA vaccine in adults aged ≥50 years
Other Childhood and Routine Vaccinations
Pertussis vaccination: Could an intranasal vaccine help curb the rising cases of whooping cough?
Does the 2+1 vaccination schedule for Haemophilus influenzae type b increase case numbers?
Wastewater poliovirus detections in Europe may reflect seasonal infection patterns rather than consistent importation
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com